OKX's products linked to U.S. stocks recorded a trading volume of 57.938 billion USDT over the 30 days ending October 22, surpassing the previous tally of 51.874 billion USDT through October 15. The majority of this volume, 56.491 billion USDT, came from stock perpetuals, while spot trading accounted for 1.447 billion USDT. Popular tickers during this period included SNDK, SOXL, and SPCX, with the storage sector leading in activity. This growth indicates increasing investor interest in stock-related digital assets on the OKX platform.
OKX's U.S. stock products recently reached a trading volume of 57.938 billion USDT over 30 days, showing strong activity in stock perpetuals and spot trading. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell today. Notable movers include COTI at Rp202 with a 3.90% increase and a typical hold time of 122 days, VET at Rp130 up 3.33%, and ATOM at Rp31,613 rising 2.92%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
